BioCentury
ARTICLE | Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

September 7, 2018 6:43 PM UTC

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) said EGP-437 did not show non-inferiority to prednisolone opthalmic solution in a Phase III trial to treat non-infectious anterior segment uveitis. The company is assessing strategic options for the product, which is a dexamethasone phosphate ophthalmic solution delivered by the EyeGate II Drug Delivery System.

The study's endpoint was the proportion of patients with an anterior cell count of zero at day 14...

BCIQ Company Profiles

Kiora Pharmaceuticals Inc.